Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies andfragments and derivatives, that exert a cytotoxic, cytostatic orimmunomodulatory on CD70 expressing cells, as well as pharmaceuticalcompositions and kits comprising the antibody, fragment or derivative. Alsodisclosed are methods for the treatment of CD70-expressing cancers andimmunological disorders, comprising administering to a subject the CD70binding agents or pharmaceutical compositions.
